Company

Cantargia AB

Headquarters: Lund, Sweden

Employees: 26

OMX: CANTA

Market Cap

kr779.9 Million

SEK as of July 1, 2024

US$73.5 Million

Market Cap History

Cantargia AB market capitalization over time

Evolution of Cantargia AB market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Cantargia AB

Detailed Description

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.

Top 1-year algo backtest: +227.67%

$10,000 in September 2023 would now be $32,767 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Cantargia AB has the following listings and related stock indices.


Stock: OMX: CANTA wb_incandescent

Stock: FSX: 7V3 wb_incandescent

Details

Headquarters:

ScheelevAegen 2

Lund, 223 63

Sweden

Phone: 46 4 62 75 62 60